eblanchard@cooley.com
Eric Blanchard practices corporate and securities law. He counsels domestic and foreign public and private companies, with an emphasis on those in the technology and biopharma industries, as well as investment banks. Eric advises clients on a variety of corporate transactions, including initial public offerings, follow-on equity offerings, pre-IPO financings, investment-grade, high-yield and convertible debt offerings, liability management transactions, proxy contests and acquisitions. He also represents public companies with respect to securities and disclosure issues and corporate governance matters.
Download full bio
Cerevel Therapeutics – $253.8 Million Follow-on Offering and Concurrent $345.0 Million Rule 144A Convertible Notes Offering
Verona Pharma – $150 Million Follow-on Offering
The Clorox Company – $1.1 Billion Unsecured Senior Notes Offering
Xometry – $287 Million Convertible Senior Notes Offering
SOPHiA Genetics – $234 Million IPO
View all
Capital Markets
Public Companies
Emerging Companies
Mergers & Acquisitions
Life Sciences
Technology
He has been absolutely brilliant. He is relaxed, measured, on top of all the issues and a delight to deal with.
Columbus School of Law - The Catholic University of AmericaJD, magna cum laude, 1999
University of MarylandBA, 1996
New York
Cooley Celebrated at The American Lawyer Industry Awards November 11, 2022
Cooley Wins Corporate Practice of the Year for Tech/Telecom November 11, 2022
The Legal 500 US 2022 Highlights Cooley June 17, 2022
Chambers USA: Capital Markets: Debt & Equity
Legal 500: Key Lawyer – Capital Markets: Equity Offerings
+1 212 479 6565
Locations